Medical, Legal, and Regulatory Review Software Market Size - By Component, By Deployment Mode, By Functionality, By Enterprise Size, By End Use, Growth Forecast, 2025 - 2034

Medical, Legal, and Regulatory Review Software Market Size

The global medical, legal, and regulatory review software market size was valued at USD 15.5 billion in 2024 and is projected to grow at a CAGR of 9.4% between 2025 and 2034. Regular and robust growth is resulting in a market is due to the increasing demand for context-driven, compliant, and collaborative review processes of promotional and scientific content in life sciences and the pharma sector. MLR processes are an established part of regulatory workflows, but the tools typically used to review MLR content have been changing considerably over the last few years.
 

Explicitly paper-based or email-driven MLR review cycles have been overshadowed by MLR review tools that offer intelligent collaboration, AI-driven compliance checks, and automated audit trails, resulting in a digital transformation for medical, legal, and regulatory reviewers that is enabling way faster workflows, a reduction in compliance risk, and reliable pathways to more efficiently commercializing products.
 

A primary growth driver is the trend toward digital and multichannel marketing. As both healthcare providers and patients consume an increasing amount of digital content on websites, email campaigns, webinars and social media, Pharma and MedTech companies are pressured to review and approve content much more rapidly, while adhering to regulatory controls. MLR software tools help ensure that every promotional assets regardless of a physician brochure or social post - has been reviewed for correctness, legality and compliance before it's distributed.
 

For instance, in June 2022, Pfizer rolled out a digital asset management (DAM) for MLR review, Veeva Vault PromoMats which allows its team to reduce approval times for healthcare professional and patients marketing materials (hard copy or digital) from 38 days to 7 days. This enabled much greater efficiency and consistency across digital, email, and website channels.
 

Medical, Legal, and Regulatory Review Software Market Trends

• The adoption of Artificial Intelligence (AI) and automation in compliance workflows is probably one of the more revolutionary developments taking place in the MLR Review software space. AI-enabled platforms can automatically proof content, intelligently tag, and reveal regulatory risk in real time, which allows medical and legal teams to uncover errors, inconsistencies, and non-compliant claims, earlier and without jeopardizing the quality of the review process.
   
• For instance, in April 2024, High Alpha Innovation created Revisto, a machine learning basis MLR platform to simplify the content review process in pharma. Revisto’s platform analyzes historical approval data and provides intelligent recommendations to writers and reviewers, prior to the formal review process. While risk validation prior to compliance review is not a new concept in this industry, what Revisto has completed allows the drug manufacturers to reduce product release times, lower compliance risk, and optimize editorial workflows while still keeping a human in the loop.
   
• The more widespread shift to modular content strategies is also providing new levels of agility and efficiencies for pharmaceutical and life sciences organizations. Instead of developing complete materials for every campaign or market, they are building libraries of pre-approved content blocks, including product descriptions, claims, and risk statements, that can be reused and remixed in whatever way is required.
   
• MLR platforms now allow for easy drag-and-drop reuse, so the material remains in full compliance and helps reduce approval turnaround times significantly while also leveraging content re-use to support a more rapid content adaptation process across the globe, which is consistent with the brand.
   
• With the rise of remote and hybrid workforces, Cloud-first deployment is now the industry standard for MLR software. Cloud-based environments provide real-time availability, collaborative editing, and global presence, which are necessary for teams dispersed across regional and time zones. Furthermore, cloud-based environments provide auditing, secure data handling and automatic version control—and accommodate for compliance when medical, legal, and regulatory stakeholders are required to collaborate. Companies, including Novartis and GSK, have adopted Cloud-native infrastructures to improve their content velocity. This goes to show the value of collaboration when reviews extend across ranges of functions.
   

Medical, Legal, and Regulatory Review Software Market Analysis

Based on component, the medical, legal, and regulatory review software market is divided into software and services. In 2024, the software segment dominated the market accounting for around 68% and is expected to grow at a CAGR of over 10% during the forecast period.
 

• The dominance is due to the increased demand for automation, compliance, and scalability in the pharmaceutical and life sciences industry. Companies have started to use more comprehensive software platforms with end-to-end digital workflow, such as content versioning, automated audit trails, real-time collaboration, and checks for compliance. The shift to cloud-based systems has spurred demand, as companies seek to adopt scalable, secure platforms that enable increased remote access and allow for collaboration among global teams.
   
• The complexity of regulatory requirements is a strong driver for the demand for software. MLR platforms have been able to offer intelligent capabilities, such as modular content reuse, region-specific approval flows, and AI-based compliance validation. These capabilities cannot be provided efficiently through service-based models.
   
• As software is a type of investment, the return on investment has been a cycle of reduced spending overtime, leading to less reliance on repetitive service engagements, and faster and more consistent content approvals. Furthermore, software is able to integrate with enterprise systems, such as CRM and digital asset management, leaving the software segment more appealing, as companies look for ways to consolidate options to manage workflows and improve compliance outputs.
   

Based on deployment mode, the medical, legal, and regulatory review software market is segmented into cloud-based, and on-premises. In 2024, the cloud-based segment dominates the market with 64% share and the segment is expected to grow at a CAGR of over 10.5% from 2025 to 2034.
 

• Cloud-based solutions provide centralized access to content, integration to content delivery systems like digital asset management and CRM including automated updates in a secure, constant state of being an up-to-date and compliant environment for all. For companies, cloud solutions significantly lessen IT infrastructure and maintenance costs and enables the scaling of their businesses without the normal barriers.
   
• As pharmaceutical companies scale and fetch new volumes of digital content across an increasingly larger and more complex regulatory environment in different geographic target markets, purpose-built cloud-based MLR platforms help provide the flexibility and responsiveness needed to navigate processes, accelerate approvals, and maintain compliance.
   
• For instance, in May 2023, Veeva Systems unveiled Vault CRM, a new, cloud-native CRM solution explicitly built for the life sciences industry. Built on the Veeva Vault platform, it has built-in features such as an AI-powered CRM Bot and a Service Center for field and hybrid representatives. Vault CRM is designed to improve engagements, increase productivity, and replace legacy CRM systems.
   

Based on functionality, the MLR review software market is segmented into medical review, legal review, and regulatory review. In 2024, the regulatory review segment is expected to dominate the market.
 

• Regulatory review thus has taken on heightened significance in the content approval process. While medical or legal reviews tend to be focused on being scientifically accurate or protecting intellectual property, for regulatory review, the aim is to ensure full compliance with rules that are region-specific and include promotional restrictions and completed submissions.
   
• In order to mitigate these demands, companies are increasingly deploying Management Library Review (MLR) software systems with functions specific to regulations such as automated tagging, audit trails, version control of materials, and integration into regulatory information management (RIM) systems. These applications not only minimize the chance of non-compliance but also increase review efficiency and state-of-readiness for health authority inspections.
   
• For instance, in January 2024, SK Life Science chose Veeva Vault Validation Management, one component of a wider Vault suite to digitize its regulatory validation processes. Moving to a digital format allowed for a centralized repository of data and a standardized set of regulated workflows, greater access and visibility to data, which ultimately increased inspection readiness and reduced compliance risks associated with regulatory validation processes. Overall, the move to a digital-first approach was much more efficient than the traditional paper-based methods.
   

In 2024, U.S. in North America dominated the medical, legal, and regulatory review software market with around 88.3% market share and generated around USD 5.9 billion in revenue.
 

• The U.S. has some of the most serious regulatory bodies in the world like the Food and Drug Administration (FDA) which requires high thresholds of content approval, advertising, and labeling. For this reason, companies biopharma and medical device companies are reliant on sophisticated MLR software to manage those requirements and reduce legal risk while improving time-to-market.
   
• The presence of cloud-based technologies, AI-driven review platforms and content publishing processes which incorporate the advancements provide additional contribution to the growth of the MLR review software market in the region.
   
• For instance, in 2024, SecureCHEK AI, a SaaS provider based in the US, provides an AI-based platform that automates pre-MLR compliance checks of promotional materials. Integrated with specific tools like Adobe inDesign and Veeva, it builds structured claims libraries and checks to ensure that the content meets all compliance checks before it is submitted for formal review. This automation can reduce the manual review burden by as much as 90%. It reduces the approval cycle time and allows pharma companies to meet and comply with the regulatory burden across multiple channels of digital marketing.
   

The medical, legal, and regulatory review software market in Germany is expected to experience significant and promising growth from 2025 to 2034.
 

• Germany is set to see significant growth from regulatory modernization, digital transformation of the life sciences sector, and increased pharmaceutical and biotech activity. Germany is the largest pharmaceutical market in Europe and encompasses many global and regional pharma, biotech, and medical device companies being forced to comply with evolving EU regulations such as the Medical Device Regulation (MDR), IDMP standards, and the future AI Act frameworks.
   
• As companies find regulations becoming increasingly data-driven and complex, they are moving from conducting manual, document-based review processes to automated, cloud-based MLR platforms, which will allow for more effectiveness in auditability, traceability, and quicker approval cycles.
   
• For instance, in January 2024, A German university hospital established a cloud computing model for the clinical domain, which is compliant with stringent EU data protection regulations. The model was tested and has been reviewed in a recently published paper in NPJ Digital Medicine. The hospital has established a valid strategy to maximize the capabilities of cloud computing, AI and scalability, while adhering to strong restrictions based on data protection regulations. To the best of our knowledge, the initiative shows a way forward in adopting secure cloud computing, while working towards sustainable cloud use for Germany's healthcare sector.
   

The medical, legal, and regulatory review software market in Japan is expected to experience significant and promising growth from 2025 to 2034.
 

• Japan's development is expected to be robust based on the country's ongoing pharmaceutical innovations, increasing acceptance of digital health technologies, and evolving regulatory landscape. As one of the largest pharmaceutical markets in the world, Japan's market share of cross-border drug development, multilingual marketing, and greater regulatory harmonization is increasing - specifically because they have adopted the International Council for Harmonisation (ICH) guidelines. Japan's regulatory body (The Pharmaceuticals and Medical Devices Agency (PMDA)) is modernizing its reviews and approvals, and actively encourages and promotes electronic submission, structured data submissions, and usage of AI-compliant systems.
   
• With Japan's rapidly aging population and the use of real-world data and digital therapeutics on the increase, there is a growing demand for compliant content licensing that is fast-tracked.
   
• Therefore, pharmaceutical, biotech, and MedTech companies readily adopted modern MLR software platforms that have reusable modular content, audit ready workflows, and regulatory compliant automated tools.
   

The medical, legal, and regulatory review software market in UAE is expected to experience significant and promising growth from 2025 to 2034.
 

• The UAE is poised for remarkable growth as the country goes through an extensive digital transformation of healthcare, with corresponding growth of the pharmaceutical and medtech sectors, and focus on regulatory modernization. Through the National Digital Health Strategy 2023–2030 and other initiatives, the UAE government seeks health innovation with an emphasis on advancing a future where Artificial Intelligence, cloud computing, and digital platforms in the healthcare ecosystem will be ubiquitous technologies.
   
• National, international, and regional pharmaceutical companies are investing in the UAE, and domestic regulators such as the Ministry of Health and Prevention (MoHAP) are reviewing content with an increasing demand for stricter and more transparent frameworks for review and approval processes. With all this activity, there is a rising demand for MLR software that provides a way to get content reviewed and approved faster, in compliance with requirements, and be audit-ready.
   
• The UAE has also become the clinical research and life sciences hub for the region, and would benefit from scalable and compliant, multilingual, cloud-based MLR platforms to share content across borders.
   
• For instance, in January 2025, At the Arab Health 2025 conference, MoHAP presented the Smart Audit Project, which employs AI to automatically review and determine compliance of architectural plans and blueprints for more than 400 clinics and hospitals; the initial accuracy is roughly 70%. The ability to speed up the regulatory approval time while ensuring compliance with global standards shows how AI-assisted review systems can optimize MLR-related workflows.
   

The medical, legal, and regulatory review software market in Brazil is expected to experience significant and promising growth from 2025 to 2034.
 

• As the largest pharmaceutical market in Latin America, Brazil is seeing a rise in demand for faster drug approvals, multi-lingual marketing materials and better regulatory compliance measures. The National Health Surveillance Agency (ANVISA) has made enduring modernization of its regulatory structure, moving closer to global standards, which are making submission and review processes more complex than ever.
   
• The pharmaceutical and medical device companies are increasingly adopting powerful MLR software systems with built-in centralized content repository, automated compliance checks, documented workflows, and audit-ready documentation.
   
• Brazil's ongoing developments promote the digitalization of health care, driven by both government visions and private sector innovation initiatives, and the adoption of cloud-based MLR systems and artificial intelligence assisted capabilities are happening faster than anyone predicted.
   
• For instance, in July 2024, ANVISA approved a pilot program with certain medicines to have QR codes that could lead to digital package leaflets. These digital package leaflets can use multiple formats (text, video, or audio) as the main message in the label/package insert; this will reduce dependence on printed inserts. Moving to digital package leaflets introduces regulatory systems delivery that can be multilingual, interactive, and version-controlled. The development also creates the demand for MLR software that can manage this change in the regulated space with a product, branded, and multi-lifecycle of marketing.
   

Medical, Legal, and Regulatory Review Software Market Share

• The top 7 companies in the medical, legal, and regulatory review software industry are LexisNexis Risk Solutions, Wolters Kluwer, Thomson Reuters, Oracle Health, GE Healthcare, Allscripts, and Optum contributing around 24.4% of the market in 2024.
   
• LexisNexis Risk Solutions is a worldwide provider of data analytics and technology solutions in many different sectors, including life sciences, legal, and healthcare. The company offers compliance and regulatory intelligence tools designed to help pharmaceutical and healthcare organizations address risk, automate various workflows, and remain compliant with the relative regulatory environment.
   
• Wolters Kluwer hails from the Netherlands and provides expert solutions in legal, tax, and health sectors. Its healthcare division features regulatory compliance software, clinical decision support, and documentation tools; the medical and regulatory functions utilize these to keep MLR reviews efficient and accurate.
   
• Thomson Reuters is typically recognized for any legal or regulatory content intelligence, Thomson also offers cloud-based platforms for reviewing content, policy tracking, risk management. Thomson also provides an array of systems in healthcare that will support compliance with regulatory standards and legal documentation requirements from both a legal and MLR perspective.
   
• Oracle Health now operates under Oracle Corporation after the purchase of Cerner. The products are focused on fully integrating clinical and financial systems along with regulatory components. Cloud-based solutions in content management, electronic health records (EHRs), and insights around compliance analytics represent the fundamental pieces for supporting MLR processes in the life sciences.
   
• GE Healthcare has software solutions addressing diagnostics, imaging, and clinical operations. GE Healthcare also develops a digital health platform that helps to support regulatory and documentation processes. For example, improved medical device compliance with regulations, and validating the healthcare communication channels for the purpose of medical/legal reviews (MLR workflows) would be two indirect contributions by GE Healthcare.
   
• Allscripts is a major healthcare IT vendor with a focus on EHR, population health, and patient engagement applications. Allscripts platforms help healthcare providers demonstrate compliance to a regulation and validate that the patient and promotional content aligns with legal and medical guidelines which are fundamentally core MLR activities.
   
• Optum provides analytics-driven services and software solutions related to healthcare management, regulatory compliance, and clinical workflows. Optum has tools that assist organizations with real-time claims audits; documentation; data governance; and ensuring organizations conjoin medical and legal content with continuously evolving regulatory frameworks.
   

Medical, Legal, and Regulatory Review Software Market Companies

Major players operating in the medical, legal, and regulatory review software industry are:

• Allscripts
• Epic Systems
• GE Healthcare
• LexisNexis Risk Solutions
• Optum
• Oracle Health
• Philips Healthcare
• Siemens Healthineers
• Thomson Reuters
• Wolters Kluwer
   

Large vendors in the medical, legal and regulatory (MLR) review software market space are, or have been, employing strategies such as partnerships, acquisitions and strategic alliances, to develop product functionality and coverage. Vendors are investing heavily in areas of advanced technology like AI-driven content verification and validation, automation of compliance assessment, SaaS cloud-native platforms, and modular content management capabilities, noting the immense increasing complexity of regulatory requirements, and facilitating the increased demand for faster, compliant and global content deployment in the pharma, biotech and medical devices sectors.
 

In particular, R&D work focuses on support for increased automation, traceability, and cross-functional collaboration, during the review process. One of the main efforts of the vendors is to provide configurable and scalable platforms, which account for local regional regulatory nuances e.g., FDA, EMA, PMDA and NMPA, and also provide consistency at a global level on the content. The regional variation along with centralized controls and cloud-based infrastructure helps our companies to reduce their approval timelines, mitigate risk and remain in compliance especially when operating in dynamic and diverse regulatory environments.
 

Medical, Legal, and Regulatory Review Software Industry News

• In June 2025, During its 2024 European Commercial Summit, Veeva announced that it will be launching MLR Bot, an AI-powered assistant built into Vault PromoMats, that will automate a variety of pre-review quality checks (e.g., brand guidelines, safety information, channel rules) in late 2025. The aim of MLR Bot is to create efficiencies that reduce review cycles and human error.
   
• In June 2025, IQVIA announced a series of AI "orchestrator agents” developed with NVIDIA, designed to automate many of the nudgy tasks required throughout clinical trial development and commercialization, such as clinical data reviews, literature scouring and market analysis. The concept of agentic AI is part of a larger trend of automating the processes of validation and review workflow that are so indispensable to any MLR functions.
   
• In May 2025, the U.S. FDA unveiled a generative AI-based scientific review tool, designed to accelerate drug and device regulatory reviews. This pilot program automates literature synthesis and clinical dossier evaluations, reducing scientific review time from days to minutes setting a precedent for AI-assisted regulatory decision-making within MLR workflows.
   
• In May 2025, the European Medicines Agency (EMA) announced six AI-centric workstreams as part of its 2025–2028 digital roadmap. These workstreams aim to integrate artificial intelligence into core regulatory review and data interoperability tasks, enhancing the speed and consistency of European MLR and dossier evaluation processes.
   
• In April 2025, the open-source community released AiReview, an AI-powered platform for systematic medical literature reviews. Though not commercial, AiReview uses large language models to perform abstract screening, title classification, and relevance scoring, making it a useful tool for MLR teams conducting publication and claim substantiation reviews.
   
• In April 2025, Klick Health (a life sciences agency) published an extensive article on how AI, especially NLP and generative models, is changing MLR review processes by automating the review cycle of claims' validation, localization and modularizations. The article shows that AI is enabling time-saving and compliant content approvals by simplifying complex regulatory and medical review processes.
   
• In April 2025, EVERSANA launched “Orchestrate MLR,” an AI-powered review automation platform developed in collaboration with AWS and Modus Create. The platform automates up to 90% of routine review tasks, integrates with Veeva Vault PromoMats, and significantly reduces content update cycles and error rates—aiming to streamline promotional and medical content approvals across global life sciences organizations.
   
• In March 2025, BASE Life Science introduced a GenAI Assistant tailored for MLR and Promotional Review Committee (PRC) functions. Designed to work within compliant frameworks like Veeva Vault, the assistant supports auto-tagging, reference checks, and compliance validation, helping content reviewers manage high-volume promotional material submissions more efficiently.
   

The medical, legal, and regulatory review software market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue ($ Mn/Bn) from 2021 to 2034, for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Software
• Services
  • Professional services
  • Managed services

Market, By Deployment Mode

• Cloud-based
• On-premises

Market, By Functionality

• Medical review
• Legal review
• Regulatory review

Market, By Enterprise Size

• SME
• Large enterprises

Market, By End Use

• Pharmaceutical companies
• Biotechnology companies
• Medical device manufacturers
• Contract Research Organizations (CROs)
• Regulatory consulting firms
• Healthcare marketing agencies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Nordics
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE